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In the 3-untranslated region, the destabilizing adenine-uri-
dine (AU)-rich elements (AREs) control the expression of sev-
eral transcripts through interactionswithARE-bindingproteins
(AUBPs) andRNAdegradationmachinery. Although the funda-
mental role for AUBPs and associated factors in eliciting ARE-
dependent degradation of cognate mRNAs has been recently
highlighted, the molecular mechanisms underlying the specific
regulation of individual mRNA turnover have not yet been fully
elucidated. Here we focused on the post-transcriptional regula-
tion of bcl-2 mRNA in human cell lines under different condi-
tions and genetic backgrounds. In the context of an AUBPs
silencing approach, HuR knockdown reduced the expression of
endogenous bcl-2, whereas unexpectedly, a bcl-2 ARE-reporter
transcript increased significantly, suggesting that HuR expres-
sion has opposite effects on endogenous and ectopic bcl-2ARE.
Moreover, evidence was provided for the essential, specific and
dose-dependent role of the Bcl-2 protein in regulating the decay
kinetics of its ownmRNA, as ascertained by a luciferase reporter
system. Altogether, the data support a model whereby the Bcl-2
protein is the major determinant of its own ARE-dependent
transcript half-life in living cells and its effect overcomes the
activity of ARE-binding proteins.
Eukaryotic cells coordinately regulate their functions to
ensure appropriate responses to stimuli. Cell signaling
involves a complex network of pathways tightly coupled to
transcriptional and translational events. Between these two
processes, modulation of the mRNA decay provides a crucial
regulatory step (1). Most importantly, regulation of mRNA is
a fundamental means of regulating both the level and the
timing of gene expression along with the metabolic state of
the cells, differentiation and stress stimuli (2). Furthermore,
dysregulation of mRNA stability has been associated with
human diseases including cancer, and inflammatory and
neurodegenerative conditions (3, 4). The clinical relevance
of post-transcriptional gene regulation by mRNA stability
has also been shown (5).
mRNA decay is a highly regulated process, established through
interactions between mRNA structures and corresponding sub-
sets of binding proteins or noncoding small RNAs (6, 7). A variety
ofmolecular determinants ofmRNAstability have beendescribed
and, to a certain extent, characterized (8). Most cis-acting mRNA
stability determinants are located in the 3-untranslated region
(3-UTR).4 Among these, the AU-rich elements (AREs) are
responsible for rapid decay of the mRNA and are recognized by a
multimeric protein complex containing HuR and other RNA-
binding proteins (9, 10). Recent studies have also indicated that
microRNAs, hybridizing preferentially to the 3-UTR, may
interact with and affect the fate of ARE-containing mRNA
(11, 12). These decay pathways are controlled by the inter-
play of function-specific as well as gene-specific RNA-pro-
tein determinants (13). Consistent with this hypothesis are
previous biochemical studies showing that ARE-containing
mRNAs can be differentially and coordinately regulated in
response to particular extracellular stimuli (14).
Given the critical function of the Bcl-2 protein in mediating
the processes of cell death and survival, in this study we focused
on its cellular post-transcriptional regulation.Alterations in the
level of Bcl-2 expression affect cell proliferation and cell death
and are determinants in the pathogenesis and progression of
several diseases such as cancer, neurodegenerative disorders, or
autoimmune diseases among others (15–17). Despite extensive
efforts, the molecular mechanisms leading to altered expres-
sion of bcl-2 in such different human pathologies have not been
elucidated. Nevertheless, many attempts have been made to
develop biological or pharmacological means of controlling
bcl-2 expression and some promising results have been ob-
tained (18–20). Therapeutic intervention targeting bcl-2would
undoubtedly benefit from a deeper understanding of themech-
anisms ruling its regulation.
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Here the post-transcriptional regulation of bcl-2 mRNA in
multiple cellular systems and under different conditions has
been explored. In detail, the small interfering RNA (siRNA)
technology was exploited to alter the cellular repertoire of the
mRNA degradation machinery to ascribe a role for proteins
potentially involved in bcl-2 mRNA post-transcriptional regu-
lation. In addition a luciferase reporter system was engineered
to address questions regarding gene-specific and function-spe-
cific mechanisms of mRNA turnover regulation. Our findings
point to a specific role of Bcl-2 in the ARE-dependent degrada-
tion of its ownmessenger in different cellular systems and con-
ditions and, interestingly, they hint at a hierarchy of different
regulatory mechanisms in modulating bcl-2mRNA half-life.
EXPERIMENTAL PROCEDURES
Plasmid Construction—A DNA fragment containing the
ARE from bcl-2 3-UTR (bARE) was cloned downstream from
the gene in the pGL4.71P vector to obtain the pGL4.71P-bARE
plasmid as described previously (21). The primer pair 5-CGT-
CTAGAACTTTTTTATGCTTACCATC-3 and 5-CGTCT-
AGACAATAGAAAAAAATCAACTT-3 was used to amplify
a 260-base pair segment containing the ARE sequence from the
human c-myc 3-UTR fragment (mARE). The latter was cloned
into the pGL4.71P plasmid above to produce the pGL4.71P-
mARE plasmid. pcDNA3-Bcl2 plasmid was constructed excid-
ing the 930-base pair fragment from pB4 (22) containing the
bcl-2 open reading frame and cloning it into the EcoRI restric-
tion site of the pcDNA3 vector (Invitrogen). pGL4.71P-cARE
plasmid containing the C2 region of the CDK5R1 3-UTR
sequence has been previously described (23).
For the FLAG-Bcl-2 construct, the bcl-2 open reading frame
(NCBI_M14745) was cloned between the XhoI and NotI
restriction sites of the pCI-NEO vector (Promega) carrying a
FLAG epitope (DYKDDDDK) with the following primers pair:
5-AAAACTCGAGATGGCGCACGCTG-3 and 5-AAAAG-
CGGCCGCTCACTTGTGGCCCAG-3. Correct orientation
of inserts was verified by sequencing.
Cell Cultures and Chemicals—Viable human embryonic kid-
ney (HEK) 293, osteosarcoma U2OS, and neuroblastoma SK-
N-BE cells were grown in completeDulbecco’smodified Eagle’s
medium (Sigma) supplemented with 10% heat-inactivated fetal
calf serum (FCS, HyClone Laboratories, Logan, UT), 2 mM glu-
tamine, 50 IU/ml penicillin, and 50 mg/ml streptomycin
(Sigma) in a humidified atmosphere of 5%CO2 at 37 °C. Burkitt
lymphoma Daudi cells and follicular lymphoma Karpas 422
(K422) cells were maintained in RPMI 1640 (Sigma) supple-
mented with glutamine, antibiotics, and FCS added under
standard conditions. The transcription blocker 5,6-dichloro-1-
-D-ribofuranosyl-benzimidazole (DRB) was purchased from
Sigma.
siRNA Transfections—3 105 cells were plated and cultured
overnight. Thereafter gene-specific siRNAs were transfected in
the presence of serum-free medium (Opti-MEM, Invitrogen)
using Lipofectamine 2000 (Invitrogen) as a carrier, according to
the manufacturer’s instructions. Cells were re-transfected after
72 h with half-doses of siRNAs as indicated. siRNA targeting
Bcl-2 (SMARTpool reagent) was purchased from Dharmacon,
Inc. (Lafayette, CO), siRNAs targeting AUF1, TTP,HuR, KSRP,
and TIA-1 were purchased from Qiagen (Hilden, Germany).
The sequences of the siRNAs used in silencing experiments
were as follows: siAUF1, AAGATTGACGCCAGTAAGAAC
(24); siTTP, CGCTGCCACTTCATCCACAAC (11); siHuR,
AAGAGGCAATTACCAGTTTCA (25); siKSRP, AGATCAA-
CCGGAGAGCAAGA (26); and siTIA1, CTGGGCTAACAG-
AACAACTAA (27).
Cell Transfection—In transient transfection experiments,
3  104/well SK-N-BE and 1  104/well HEK293 cells were
co-transfected in triplicate in 96-well plateswith equal amounts
(200 ng) of the pGL4.71P constructs and pGL3P control plas-
mid. 24 h post-transfection cells were lysed and luciferase activ-
ity was measured as described in the following section. To
establish stably transfectedHEK293 clones, 80% confluent cells
were co-transfected with 10 g of each pGL4.71P plasmid and
10 g of pcDNA3 vector carrying the Geneticin (G418) resist-
ance gene. Cells were selected for 3 weeks in the presence of 0.8
mg/ml G418 (Invitrogen). Resistant cells gave rise to a set of
pGL4.71P-bARE and pGL4.71P-mARE clones. The expres-
sion of the Renilla hRlucP gene was analyzed in each clone by
luciferase assays as described afterward. C7, B4, and D21
clones, stably transfected with pGL4.71P, pGL4.71P-bARE,
and pGL4.71P-mARE, respectively, were selected for further
experiments due to similar Renilla luciferase activity. Lipo-
fectamine 2000 (Invitrogen) was used as transfection reagent in
all the aforementioned experiments according to the manufac-
turer’s instructions. Daudi cells stably expressing Bcl-2 protein
were obtained by electroporating pcDNA3-Bcl2 plasmid in a
Bio-Rad Gene Pulser at a setting of 220 V/960 microfarads.
After electroporation, cells were incubated for 5 min on ice,
then placed in 10 ml of RPMI supplemented with 20% FCS.
Transfected Daudi cells were supplemented with 1 mg/ml
G418 to select stably transfected clones.
Measurement of LuciferaseActivity—After co-transfection of
the two luciferase plasmids, both firefly and Renilla luciferase
activities were measured sequentially from a single aliquot of
the cell lysate using the Dual-Glo Luciferase Reporter Assay
System (Promega) according to the manufacturer’s instruc-
tions. Relative Renilla luciferase light output was normalized to
firefly luciferase output as well as to the protein concentration.
Data were expressed as mean S.E. Statistical significance was
calculated by using a Student’s t test.
RNA Isolation, cDNA Synthesis, and Real Time Quantitative
PCR—Total cellular RNA was extracted at the indicated
times using the NucleoSpin RNA II columns (Macherey-Na-
gel, Du¨ren, Germany) according to themanufacturer’s instruc-
tions. The RNA was then treated with RNase-free DNase
(Invitrogen) and analyzed spectroscopically and by gel electro-
phoresis for purity and integrity, respectively. For cDNA syn-
thesis, 0.1 g/l total RNA, DNase treated, was reverse-tran-
scribed with the High Capacity cDNA Archive Kit (Applied
Biosystems, Foster City, CA) using standard conditions set by
the manufacturer in a total volume of 50 l. cDNAs levels of
Renilla and firefly luciferases, bcl-2, and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) were determined using
Real Time PCR, through TaqMan technology (Applied Biosys-
tems), using specific primers and probes. Reporters and bcl-2
amplification datawere normalized versus the expression of the
Bcl-2 Protein Regulates bcl-2 ARE over HuR
JULY 31, 2009•VOLUME 284•NUMBER 31 JOURNAL OF BIOLOGICAL CHEMISTRY 20947
 at Università degli studi di M
ilano on July 29, 2009 
w
w
w
.jbc.org
D
ow
nloaded from
 
housekeeping gene GAPDH. Each reaction was performed in
triplicate for a better statistical reliability of results. The PCR
were carried out in an ABI Prism 7000 Sequence Detection
System (Applied Biosystems). The amplification plot and cycle
threshold data were elaborated with ABI Prism 7000 SDS soft-
ware (version 1.1).
mRNA Decay Assays—In mRNA decay assays cells were
treated with DRB (20 g/ml final concentration) 24 h post-
transfection to suppress the transcription of the luciferase
reporter gene. Cells were harvested at 0, 3, 5, and 7 h after
treatment with DRB and RNA isolated for quantitative reverse
transcriptase-PCR analysis.
Flow Cytometric Analysis—2  106 electroporated Daudi
cells were harvested and washed with 1 phosphate-buffered
saline. Cells were resuspended in a 3% paraformaldehyde solu-
tion and incubated on ice for 1 h. Fixed cells were pelleted and
washed in pre-cooled 1 phosphate-buffered saline, then
resuspended in 500 l of RPMI medium containing 20% FCS
and 0.5%Tween (Sigma). Cells were pelleted, resuspended in 50
l of FCS, and incubated 15 min at room temperature. Perme-
abilized cells were centrifuged and the pellet was resuspended
RPMI medium containing 20% FCS, 0.5% Tween, and 50 l of
fluorescein-conjugated 1:50 diluted anti-human Bcl-2 mono-
clonal antibody (Dako Italia, Milan, Italy). The cells were incu-
bated at room temperature for 1 h in the dark, then pelleted and
washed four times in pre-cooled 1 phosphate-buffered saline
at 4 °C. Washed cells were resuspended in 350 l of 1 phos-
phate-buffered saline before flow cytometric analysis.
Western Blot and Co-immunoprecipitation (IP) Assays—The
Western blot assayswere performedunder standard conditions
as previously described (28). Protein concentrations were
measured using the Micro BCA Protein Assay (Thermo Fisher
Scientific, Rockford, IL). Images of Western blots were
acquired and analyzed using the Bio-Rad Versadoc Imaging
System. Protein band densitieswere quantified using theQuan-
tity One software provided with the station. For IP assays, pro-
tein A/G UltraLink Resin (Thermo Fisher Scientific) was pre-
coated with 1.6 g of IgG1, HuR, or Bcl-2 mouse monoclonal
antibodies (Santa Cruz Biotechnology), washed with lysis
buffer (20mMTris-HCl, pH7.2, 50mMKCl, 10mMMgCl2, 0.5%
Nonidet P-40, 1 mM dithiothreitol, protease, and RNase inhib-
itors), and incubatedwith 0.5ml of cell lysates (16 h, 4 °C). After
washes withmodified lysis buffer (20mMTris-HCl, pH 7.2, 300
mM KCl, 10 mM MgCl2, 0.5% Nonidet P-40), samples were
denatured, fractionated by SDS-PAGE, and analyzed by West-
ern blot. For FLAG IP assays, 0.5 ml of U2OS cell lysate (10 mM
Hepes, pH 7.6, 100 mM KCl, 5 mMMgCl2, 2.5 mM EDTA, 2 mM
dithiothreitol, protease, and RNase inhibitors) were incubated
for 2 h at 4 °Cwith proteinA/GUltraLinkResin (ThermoFisher
Scientific), precoated with 2.0 g of FLAG M2 mouse mono-
clonal antibody (Sigma). Samples were then washed and pro-
cessed as described above.
RESULTS
ARE-dependent Destabilizing Activity on Reporter Transcript—
Luciferase gene containing plasmids were generated and
employed in both transient and stable transfection experiments
in different human cell lines to validate the suitability of this
reporter system to study the ARE-dependent destabilizing
activity. Among reporters used in mammalian cells, the Renilla
reniformis hRlucP luciferase gene incorporates a protein degra-
dation sequence conferring high instability to the encoded
reporter protein (29) and thus suitable for studying the rate of
reporter response to cellular stimuli.
A DNA fragment containing the ARE bcl-2 (bARE) was
cloned downstream of the stop codon of Renilla luciferase gene
in the pGL4.71P vector to obtain the pGL4.71P-bARE plasmid.
A secondARE fragment from c-myc 3-UTRwas inserted in the
same position in the pGL4.71P vector to obtain the pGL4.71P-
mARE plasmid, used as a control. Both the Renilla luciferase
empty vector (pGL4.71P-NO ARE) and the ARE-containing
constructs (Fig. 1A) were transiently co-transfected with the
pGL3P firefly luciferase reporter plasmid into human neuro-
blastoma SK-N-BE and HEK293 cells. The Renilla luciferase
activity was normalized to firefly luciferase activity, as shown in
Table 1 and supplemental Table S1. The insertion of the ARE
fragments downstream of the reporter gene led to a decrease in
the Renilla luciferase activity in both transiently transfected
human cell lines: bARE was able to reduce the reporter activity
to about 50% and mARE to 32 and 45% in SK-N-BE and
HEK293 cells, respectively (Fig. 1B). The destabilizing activity
of ARE sequences was shown in HEK293 transiently trans-
fected cells after the addition of the transcriptional blocker
DRB. The relative luciferase activity normalized over protein
concentration is shown in Fig. 1C. RlucP mRNA half-life was
halved in the presence of bARE (Fig. 1D) following the same
kinetics as the reporter protein activity, thus assessing the role
of bARE on mRNA decay rates and validating the reporter sys-
tem to study ARE-containing mRNAs.
Role of AUBPs in Regulating bARE Reporter Transcript
Stability—ThreeHEK293clones, namelyC7-NOARE,B4-bARE,
and D21-mARE, stably transfected with pGL4.71P-NO ARE,
pGL4.71P-bARE, and pGL4.71P-mARE, respectively, expressed
similar levels of reporter gene, as verified by real time reverse
transcriptase-PCR and luciferase activity assays (not shown). In
these stably transfectedHEKclones a subset of either destabilizing
or stabilizing AUBPs were silenced by siRNAs.
AUF1, expressed in four isoforms arising from differential
splicing (30), was silencedwith different siRNAdoses by target-
ing the exon 1 region (siAUF1), present in all AUF1 isoforms.
Albeit, the silencing effect was stronger on p45AUF1 and
p40AUF1 isoforms, possibly less abundant in this cell line, as
evaluated by Western blot (Fig. 2A); siAUF1 treatment signifi-
cantly increased the Renilla luciferase activity (Fig. 2B) in
B4-bARE and, to a lesser extent in D21-mARE cells.
Furthermore,we considered the role ofTIA-1, a translational
silencer that also turns mRNA liable to the decay machinery
(31). A reduction in TIA-1 protein level (Fig. 3A) with a siRNA
(siTIA1), could increase the Renilla luciferase activity in
B4-bARE cells from 60 to 80% compared with vehicle-treated
cells (Fig. 3B). In contrast, TTP and KSRP were silenced with-
out significant changes to luciferase activity, although the tar-
geted protein levels decreased using siRNA treatment (data not
shown).
Silencing of HuR (siHuR) brought about quite unexpected
findings. In contrast to the stabilizing effect of HuR reported in
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20948 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 284•NUMBER 31•JULY 31, 2009
 at Università degli studi di M
ilano on July 29, 2009 
w
w
w
.jbc.org
D
ow
nloaded from
 
the literature (32), its down-regulation led to a 2-fold increase
in the Renilla luciferase activity in B4-bARE cells (Fig. 4B). A
double siRNA treatment with 50 25 nM doses showed a fur-
ther increase in luciferase activity.
Based on the well established HuR stabilizing activity on
ARE-containing mRNA (32), a decrease in reporter levels in
both B4-bARE and D21-mARE clones was expected. The
unforeseen findings inspired a detailed analysis of the mecha-
nism responsible for increased reporter activity in B4-bARE
siHuR-treated cells. As previously shown (33, 34), and con-
firmedhere (Fig. 4,A andC), HuR silencing caused a decrease in
the expression of a number of genes, including bcl-2. This
reductionwas also confirmed by bcl-2mRNA levels in all tested
cell clones (Fig. 4D). To evaluate whether mRNA quantitative
changes depended on altered mRNA stability, a transcriptional
blocker (DRB) was used in siHuR experiments. Real time
reverse transcriptase-PCR assays on RNA extracted from
treated cells clearly indicate that siHuR is able to destabilize
endogenous bcl-2mRNAas shown in Fig. 4E. Conversely, when
Rluc-bARE transcript levelsweremeasured in siHuRB4-bARE-
treated cells, an increase comparable with the extent of the
reporter activity increment was found (Fig. 4F).
Data presented herein and by others (35) show that HuR
silencing can determine decreased expression of the mRNA
and the relevant protein levels of a number of genes. The
hypothesis that increased luciferase activity restricted to the
bARE reporter may arise from the dominant effect of low Bcl-2
FIGURE 1. Validation of the reporter system. A, schematic representation of Renilla luciferase plasmids generated to investigate the effect of ARE
sequences on the expression of the reporter gene. B, SK-N-BE and HEK293 human cell lines were transiently transfected with equal amounts of pGL3P
firefly luciferase vector and pGL4.71P Renilla luciferase plasmids. Renilla luciferase normalized to firefly luciferase activity is shown with the normalized
activity of the pGL4.71P-NOARE plasmid being taken as 1. Data are themean of four independent experiments in triplicate S.E. (error bars). **, p 0.01
comparedwith the corresponding pGL4.71P-NOARE value. C, time course of luciferase activity in HEK293 cells after DRB addition 24 h post-transfection.
Renilla luciferase was normalized to firefly luciferase activity and to protein content. Data are the mean of three independent experiments S.E. (error
bars). D, time course of hRlucP mRNA decay in HEK293 cells after DRB addition 24 h post-transfection. Total RNA was analyzed for Renilla luciferase
transcript expression by real time quantitative PCR and normalized to firefly luciferase mRNA levels at each time point after DRB addition. Data are the
mean of three independent experiments S.E. (error bars).
TABLE 1
Ratio of luciferase activities in transiently transfected human cell
lines
SK-N-BE and HEK293 cells were plated and after 24 h co-transfected with firefly
and Renilla luciferase reporter plasmids as described under “Experimental Proce-
dures.” 24 h post-transfection cells were lysed and luciferase activities measured in
a counter plate reader for luminometry. Renilla luciferase activity values were nor-
malized to firefly luciferase activity (i.e.Renilla luciferase light units/firefly luciferase
light units) and the data from four independent experiments are shown as the ratio
mean S.E.
Renilla luciferase
constructs
Renilla/firefly luciferase activity
SK-N-BE cells HEK293 cells
pGL4.71P 1.71 0.17 1.70 0.36
pGL4.71P-bARE 0.88 0.06 0.85 0.18
pGL4.71P-mARE 0.52 0.05 0.75 0.15
Bcl-2 Protein Regulates bcl-2 ARE over HuR
JULY 31, 2009•VOLUME 284•NUMBER 31 JOURNAL OF BIOLOGICAL CHEMISTRY 20949
 at Università degli studi di M
ilano on July 29, 2009 
w
w
w
.jbc.org
D
ow
nloaded from
 
expression on the degradation rate of the bARE mRNA has
been addressed.
Bcl-2 Role in Regulating bARE Reporter Transcript—siRNAs
directed against bcl-2 mRNA (siBcl2) were transfected at final
concentrations of 50 and 100 nM into cell clones. Analysis of the
Bcl-2 protein by Western blot showed effective and specific
siBcl2 silencing (Fig. 5A). Lowering the amount of Bcl-2 signif-
icantly increased the bARE reporter activity (Fig. 5B), attesting
the direct role of the Bcl-2 protein in triggering the degradation
of bARE mRNA. The specificity of the effect of siBcl2 on the
bARE reporter was assayed by lipofecting cells with a second
siRNA dose after the first siBcl2 treatment. Half-doses of
siRNA, added 72 h after the first siBcl2 lipofection, further
down-regulated endogenous bcl-2mRNAand protein in all cell
clones as assayed by real time reverse transcriptase-PCR (data
not shown) andWestern blot, respectively (Fig. 5C). The stron-
ger silencing of Bcl-2 caused a higher increase of luciferase
activity restricted to B4-bARE reporter cells, as the level of
reporter gene expression in C7-NO ARE and D21-mARE
clones was unchanged compared with vehicle-treated cells
(Fig. 5, B and D).
To further establish the molecular mechanism underlying
bcl-2 post-transcriptional regulation by its own gene product,
Bcl-2 expression was rescued in B4-bARE cells upon siBcl2
treatment. Bcl-2 was expressed ectopically by transiently trans-
fecting cells with pcDNA3-Bcl2, a plasmid encoding for a wild
type Bcl-2 protein, but lacking the bcl-2 3-UTR, and thus
refractory to the bARE-dependent regulation (Fig. 5E). As
shown in Fig. 5F, in Bcl2-silenced cells the restored expression
of Bcl-2 was able to down-regulate Renilla luciferase activity to
the levels of unsilenced cells.
FIGURE2. Increased luciferase activitybyAUF1 silencing.A, HEK293 stably
transfected cells lipofected with siAUF1 for 72 h and half-doses for a further
72 h were Western blot analyzed to test the levels of AUF1 isoforms. Upper
panel, the gel refers to B4-bARE cells, similar findings were obtained from all
siAUF1-treated clones in three independent experiments. Lower panel, den-
sitometric quantifications of AUF1Western blot bands, normalized to house-
keeping loading control protein, are shownaspercentageof unsilenced cells.
The data shown are themean of three independent experiments S.E. (error
bars). B, Renilla luciferase activity was measured and data normalized to pro-
tein content. Values are expressed as relative luciferase activity versus cells
treated with lipofectamine only. Data are the mean of three independent
experimentsS.E. (error bars). *,p0.05; **,p0.01 comparedwith vehicle-
treated cells.
FIGURE 3. Increased luciferase activity byTIA-1 silencing.A, HEK293 stably
transfected cells lipofected with siTIA1 for 72 h were lysed and cell extracts
analyzed byWestern blot to test the level of TIA-1 silencing. Upper panel, the
gel is representative of B4-bARE cells, similar findings were obtained from all
siTIA1-treated clones in three independent experiments. Lower panel, densi-
tometric quantifications of TIA-1 Western blot bands, normalized to house-
keeping loading control protein, are shownaspercentageof unsilenced cells.
The data shown are themean of three independent experiments S.E. (error
bars). B, Renilla luciferase activity wasmeasured. Data normalized as in Fig. 2B
are themeanof three independentexperimentsS.E. (error bars). **,p0.01
compared with vehicle-treated cells.
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The dose-dependent role of Bcl-2 in regulating bARE-contain-
ingmRNAhalf-lifewas studied in another engineered cellular sys-
tem. Cell clones expressing, in basal conditions, different levels of
Bcl-2 protein were generated. We then correlated Bcl-2 levels to
reporter activity of Renilla luciferase in transiently transfected
cells. In particular, Daudi Burkitt lymphoma cells, not expressing
Bcl-2 protein (36), were electroporated with pcDNA3-Bcl2 plas-
mid and clones stably expressing different levels of Bcl-2 protein
were created after G418 selection. The Bcl-2 protein expression
level was screened by flow cytometric analysis of immunostained
cells (data not shown) and Western blot analysis of individual
clones (Fig. 6A). One Daudi clone
expressinghigh levels ofBcl-2protein
(B7), a secondone expressing low lev-
els of Bcl-2 protein (A9), and a mock
cell clone (D4) were transiently
transfected with Renilla luciferase
plasmids as well as pGL3P control
vector. Luciferase activity was
measured to evaluate the correla-
tion between different levels of
Bcl-2 expression and the activity of
the reporter transcript. In this
study, the ARE containing C2
region of the CDK5R1 3-UTR
sequence (23) was used as a control
(pGL4.71P-cARE), because the high
level of c-myc expression in Daudi
cells might interfere with the
metabolism of the reporter tran-
script containing the c-myc 3-UTR.
Daudi clones were electroporated
with reporter plasmids and lucifer-
ase activity was measured (Fig. 6B).
An inverse correlation between the
bARE-reporter activity and the cel-
lular amount of Bcl-2 protein was
found, thusdemonstrating thedose-
dependent role of Bcl-2 in destabi-
lizing bARE-containing mRNA in
living cells. No significant luciferase
change according to Bcl-2 levels was
obtained in c-ARE reporter cells.
To getmore insight into themech-
anistic understanding of bcl-2 regula-
tion, we then tested whether HuR
associates with Bcl-2 by co-immuno-
precipitation. U2OS cells were tran-
siently transfected with a FLAG-Bcl2
expression plasmid, cell extracts were
immunoprecipitatedwith anti-FLAG
incubated proteinA/G resin and ana-
lyzed by Western blotting. The
expressionplasmid encodingonly the
FLAG epitope was also transfected as
a control to determine the back-
ground binding activities. As shown
in Fig. 7A, HuR co-immunoprecipi-
tatedwithFLAG-Bcl2.Tobetter assess theHuR/Bcl-2 interaction,
wenextconducted IPassaysonendogenousproteins inK422cells.
Wild type Daudi cells were used in IP assays as negative controls.
Cell extracts prepared from both cell lines were immunoprecipi-
tated with anti-HuR and anti-Bcl2-coated A/G resin.Mouse IgG-
bound resinwas used as negative control. Sampleswere separated
by electrophoresis and probed for HuR. IP using anti-Bcl2 anti-
body revealed thatHuRco-immunoprecipitatedwith endogenous
Bcl2, as shown in Fig. 7B. No interaction was found in samples
from Daudi cells used as a negative control not expressing Bcl-2
protein.
FIGURE 4. Specific increase of bARE reporter activity by silencing HuR. A, stably transfected HEK293
clones treatedwith siHuR for 72 hwere lysed and Renilla luciferase activity wasmeasured. Cells were given
a second half-dose of siHuR and lysed after further 72 h.Western blot analysis of HuR and Bcl-2 shown here
refers to B4-bARE cells. Similar results were achieved in all siHuR-treated clones, in four independent
experiments. B, Renilla luciferase activity was normalized as described in the legend to Fig. 2B. Data are the
mean of four independent experiments S.E. (error bars). C, densitometric quantification of Bcl-2 and HuR
Western blot bands, normalized to housekeeping loading control proteins, are shown as percentage of
unsilenced cells. The data shown are themean of four independent experiments S.E. (error bars).D, total
RNAwas analyzed for bcl-2mRNA expression by real time quantitative PCR in cells treated with siHuR as in
A. Data normalized versus GAPDH are expressed as relative bcl-2 mRNA level versus vehicle-treated cells.
Data are themean of three independent experiments S.E. (error bars). E, rate of bcl-2mRNA degradation
in B4-bARE cells treated with siHuR and further with DRB for transcription inhibition was determined as in
D. Data are the mean of three independent experiments S.E. (error bars). F, total RNA was analyzed for
Renilla luciferase mRNA expression by real time quantitative PCR in B4-bARE cells treated with siHuR as in
A. Data normalized versus GAPDH are expressed as relative Renilla luciferase mRNA level versus vehicle-
treated cells. Data are the mean of three independent experiments  S.E. (error bars). **, p  0.01 com-
pared with vehicle-treated cells.
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According to the findings, Bcl-2 is essential for the bARE-de-
pendent degradation of the bcl-2mRNA. Moreover, the rate of
the messenger decay is inversely correlated to the protein
amount, thus providing a potential
mechanism for gene-specific regu-
lation of mRNA decay. Bcl-2 may
dynamically associate to HuR to
wield this regulatory role.
DISCUSSION
mRNA decay processes play a
key role in the global control of
gene expression and in regulating
cellular response to exogenous
signals (1, 2). Recent findings have
been remarkable in identifying the
molecular components, elucidat-
ing the “mechanics” and spotting
the cellular sites of mRNA turn-
over (8, 37, 38). According to the
“RNA Regulon” theory multiple
functionally related mRNAs are
coordinately regulated by trans-
acting factors (39). However,
despite these tremendous achieve-
ments, the mechanisms by which
cells coordinate the expression of
specific genes in response to stim-
uli by post-transcriptional regula-
tion remain unclear in many cases.
One enduring question is how
individual and functionally related
ARE-containing mRNAs can be dif-
ferentially regulated in response to a
variety of stimuli. An intriguing
hypothesis has been proposed (13,
40) for the mechanism underlying
the gene-specific regulation ofARE-
containing mRNA turnover. On the
basis of biochemical studies, Bcl-2
protein triggers theARE-dependent
degradation of its own transcript
and regulates the rate of decay
in a dose-response manner. The
molecular mechanism by which
cellular Bcl-2 regulates the rapid
degradation of its own mRNA
remains poorly defined. Here evi-
dence is provided on the role of the
Bcl-2 protein in leading the degra-
dative enzymatic machinery to its
cognate mRNA in cells under dif-
ferent genetic and growth condi-
tions. This is of particular im-
portance because of the critical
function of Bcl-2 in a number of
(pato-)physiological processes (41,
42). Most relevant are the mecha-
nisms underlying its altered level of expression in a variety of
human diseases and its tuning the response to different stimuli
and chemotherapy treatments.
FIGURE 5. Increased bARE reporter activity by Bcl-2 silencing restored by Bcl-2 rescuing. A, stably trans-
fected HEK293 clones were treated with siBcl2 for 72 h and the expression of Bcl-2 was analyzed by Western
blot. Upper panel, the gel shown here refers to B4-bARE-treated cells, similar findings were obtained with all
siBcl2-treated clones in three independent experiments. Lower panel, densitometric quantifications of Bcl-2
Western blot bands, normalized to housekeeping loading control protein, are shown as percentage of unsi-
lenced cells. The data shown are the mean of three independent experiments  S.E. (error bars). B, Renilla
luciferase activity wasmeasured and data analyzed as described in the legend to Fig. 2B. Data are themean of
three independent experiments S.E. (error bars). C, HEK293 clones treated twice with siBcl2 were lysed after
144 h and Bcl-2 analyzed by Western blot as in A. Upper panel, the gel shown here refers to B4-bARE-treated
cells, similar findings were obtained with all siBcl2-treated clones in four independent experiments. Lower
panel, densitometric quantifications of Bcl-2Western blot bands, normalized to housekeeping loading control
protein, are shown as percentage of unsilenced cells. The data shown are the mean of four independent
experiments S.E. (error bars).D, Renilla luciferase activity wasmeasured and data normalized as above. Data
are the mean of four independent experiments  S.E. (error bars). E, B4-bARE cells were treated with 80 nM
siBcl2 for 24 h and then transiently transfected with pcDNA3-Bcl2 plasmid for 48 h before sample collection.
Bcl-2 levelswereassayedbyWesternblot.F,Renilla luciferaseactivitywasanalyzedas above.Data are themean
of three independent experiments S.E. (error bars). *,p0.05; **,p0.01 comparedwith vehicle-treated cells.
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The object of this study is therefore to gain deeper compre-
hension of the post-transcriptional regulation of the bcl-2 tran-
script. Among the broad spectrum of determinants of bcl-2
mRNA half-life, we investigated the role of AUBPs required for
the ARE-dependent mRNA degradation (9) with respect to
bARE.MicroRNAshave also been implicated in the decay proc-
ess of ARE-containingmessengers (12) although their potential
role has not been considered in this study.
The silencing of AUF1 and TIA-1 led to an increase in the
bARE reporter activity. Most likely, down-regulation of the
decay determinants stabilized the ARE-containing target. In
particular, siRNA targeting AUF1 was able to down-regulate
predominantly p40AUF1/p45AUF1 isoforms and this in turn
determined an increase in luciferase activity of the bARE
reporter and, to a lesser extent, of the mARE clone. These
results, in keeping with others (24), provide additional support
to the theory that the relative levels of individual isoforms,
rather than the absolute amount of AUF1, determine mRNA
stability of ARE-containing transcripts, consistent with the dif-
ferent ARE-binding functions of the isoforms.
It was not possible to ascribe a role for TTP and KSRP in
regulation of bARE mRNA as their silencing had no effect on
the reporter activity. Supplementary investigation is needed to
explain these unexpected results because we have formerly
shown by UV cross-linking and RNA immunoprecipitation
assays that both AUBPs are able to bind to the bARE transcript
(21).
Unanticipated findings were observed when HuR was
silenced. This AUBP is known as a mRNA stabilizer (32) thus a
decrease of ARE-containing reporter following HuR silencing
was foreseen. Quite unexpectedly, HuR silencing caused spe-
cific up-regulation of the bARE reporter. Indeed, the mARE
transcript decay rate was notmodified by siHuR, as observed by
others (43). We speculate that opposite actions of different
AUBPs modulating mARE turnover may produce this net null
result, but deeper investigation is needed.
The increased luciferase activity in bARE reporter cells
prompted us to envisage a potential interplay between gene-
specific and function-specific mechanisms of mRNA turnover
regulation. In particular, we hypothesized that the HuR silenc-
ing effect on endogenous bcl-2mRNAmight, in turn, influence
the bARE-specific reportermRNA turnover. Indeed, the silenc-
ing of HuR caused a significant reduction of the levels of Bcl-2
protein and mRNA due to decreased mRNA stability. Alto-
gether these results proved the stabilizing activity of HuR on
endogenous bcl-2mRNA but also revealed the opposite effects
of HuR silencing on ectopic and endogenous bcl-2 ARE. As a
consequence of HuR silencing, the Bcl-2 down-regulation can
mediate a stabilizing effect on the bARE reporter mRNA that
increases its luminescence. Most importantly, the unpredicted
increase of bARE reporter activity following HuR silencing
hints at a possible picture where the gene-specific effect trig-
gered by endogenousBcl-2 down-regulation is dominant on the
function-specific outcome of HuR silencing.
FIGURE 6. Inhibition of luciferase activity in Daudi clones expressing dif-
ferent Bcl-2 levels. A, Bcl-2 protein levels were determined by Western blot
inDaudi cells stably transfectedwithpcDNA3-Bcl2. Foldof Bcl-2 expression in
A9, B7, and D4 clones compared with follicular lymphoma K422 cells was
obtained by densitometric analysis. B, Daudi clones electroporated with
Renilla luciferase plasmids and pGL3P control vector were lysed after 48 h for
luciferase activity determinations. Data were normalized as described in the
legend to Fig. 1B. Data are themeanof three independent experiments S.E.
(error bars).
FIGURE 7. HuR co-immunoprecipitation with Bcl-2 protein. A, U2OS cells
were transfectedwith FLAG or with FLAG-Bcl2 expressing plasmid. 48 h later,
cell lysates from transfected and untransfected cells were immunoprecipi-
tated with anti-FLAG-incubated A/G resin. HuR immunoprecipitates were
assessedbyWesternblotusinganti-HuRantibody (middlepanel). As a control,
the amounts of HuR were verified in total cell lysates (upper panel) and the
expression of FLAG-Bcl2 was confirmed using an anti-FLAG antibody (lower
panel). Themigration of the immunoglobulin light chain (IgG L.C.) is indicated
at 25 kDa. B, cell lysates from K422 and Daudi cells were immunoprecipitated
with the relevant primary antibody as indicated. Immunoprecipitates were
subjected to Western blot for HuR. A sample of each cell lysate, labeled as
Input, was also analyzed. The migration of the immunoglobulin heavy chain
(IgG H.C.) and HuR are indicated at 50 and 36 kDa, respectively.
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Weaddress this hypothesis and provide evidence of the spec-
ificity and the efficacy of the Bcl-2 protein in regulating the
decay rate of its ownmRNA in genetically defined cell lines and
clones. Both transiently and stably transfected cells expressing
the 3-modified reporter gene showed the Bcl-2 specific regu-
lation in different cell lines. The siRNA silencing of Bcl-2
expression in either transiently or stably transfected clones
showed the increase of the bARE-reporter luminescence in a
dose-response fashion. The Bcl-2 destabilizing function on its
own mRNA observed in siBcl2-treated stably transfected
clones was directly proved by restoring Bcl-2 expression in Bcl-
2-silenced cells and by ectopically expressing the bcl-2 gene in
(bcl-2/) Daudi cells.
Finally, HuR and Bcl-2 physically interact with each other, as
ascertained by co-immunoprecipitation experiments, with
Bcl-2 counteracting HuR activity on bARE, as indicated by the
unanticipated findings that siHuR led to an increase of Rluc-
bARE transcript levels due to reduced levels of Bcl-2. Alto-
gether these data suggest a mechanism whereby Bcl-2 might
displace HuR from its targets localized in the bARE sequence.
In human cellular systems with diverse genetic backgrounds
and differentiation conditions, the Bcl-2 protein was determi-
nant to regulate the rate of bARE turnover, as evaluated by the
reporter activity. A negative feedback mechanism finely mod-
ulating Bcl-2 levels by a bARE-specific regulation is substanti-
ated by the data presented herein and suggest that negative
feedback might be a foremost general principle in mammalian
regulation of mRNA turnover (44).
The results achievedmight have implications for other ARE-
containing RNAs, thus shedding light on the molecular mech-
anism by which gene-specific regulation of mRNA decay
occurs. This is a crucial issue in the investigation of determi-
nants ofmRNAstability and gene expression regulation overall.
In conclusion, we can envisage a hierarchic network of dif-
ferent AUBPs and associated factors affecting bARE RNA sta-
bility involving Bcl-2 protein itself as the major determinant of
its own transcript half-life in living cells. This mechanism
would provide an autoregulatory loop able to rapidly vary the
Bcl-2 level in response to different stimuli. Interestingly, the
expression of many RNA-binding proteins has been recently
suggested to be post-transcriptionally self-regulated (45–47),
and tightly interdependent, suggesting a circuitry of self- and
cross-regulatory interactions (48). Altogether these data reveal
a hierarchy in themechanismof post-transcriptional regulation
of gene expression, at least for ARE-containing mRNAs, with
the gene-specific elements prevailing on the function-specific
factors.
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